Projecting future drug expenditures - 2010

American Journal of Health-System Pharmacy

Volumn 67, Issue 11, 2010, Pages 919-928

  Hoffman, James M ^a,b   Doloresco, Fred ^c,d   Vermeulen, Lee C ^e,f   Shah, Nilay D ^g,h   Matusiak, Linda ⁱ   Hunkler, Robert J ⁱ   Schumock, Glen T ^j,k  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c U of WI School of Pharmacy   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e University of Wisconsin Health   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g Mayo Clinic   (United States)

^h MAYO CLINIC   (United States)

ⁱ IQVIA   (United States)

^j Department of Pharmacy Practice ^*  (United States)

^k UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

Costs; Drugs; Economics; Health benefit programs; Pharmacy, institutional, hospital; Product development

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANASTROZOLE; ATORVASTATIN; AZACITIDINE; BELIMUMAB; BENDAMUSTINE; BEVACIZUMAB; BOCEPREVIR; BORTEZOMIB; CANAKINUMAB; CETUXIMAB; CHICKENPOX VACCINE; CLADRIBINE; DABIGATRAN; DAPTOMYCIN; DENOSUMAB; DOCETAXEL; DONEPEZIL; DOXORUBICIN; ENOXAPARIN; FULVESTRANT; GEMCITABINE; GENERIC DRUG; HIRULOG; INFLIXIMAB; INFLUENZA VACCINE; IODIXANOL; IOHEXOL; IPILIMUMAB; IXABEPILONE; LAQUINIMOD; LATANOPROST; LEUPRORELIN; LEVOFLOXACIN; LINEZOLID; LIRAGLUTIDE; LOSARTAN POTASSIUM; MOTAVIZUMAB; NEW DRUG; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OLANZAPINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PARICALCITOL; PEMETREXED; PIOGLITAZONE; PIPERACILLIN PLUS TAZOBACTAM; RANIBIZUMAB; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; RIVAROXABAN; TAMSULOSIN; TEMOZOLOMIDE; TEMSIROLIMUS; TICAGRELOR; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VICRIVIROC; ZAFIRLUKAST; ZOLEDRONIC ACID; DRUG;

ACUTE CORONARY SYNDROME; AMBULATORY CARE; ANTICOAGULANT THERAPY; BIOLOGICAL THERAPY; CANCER THERAPY; CINCA SYNDROME; COMPARATIVE EFFECTIVENESS; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG COST; DRUG DEVELOPMENT; DRUG LEGISLATION; DRUG SAFETY; DRUG UTILIZATION; ECONOMIC RECESSION; FORECASTING; HEALTH CARE POLICY; HEPATITIS C; HOSPITAL; HOSPITAL RUNNING COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA A (H1N1); LUPUS ERYTHEMATOSUS; MELANOMA; MULTIPLE SCLEROSIS; OSTEOPOROSIS; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; TREND STUDY; UNITED STATES; ARTICLE; DRUG APPROVAL; ECONOMICS; HEALTH CARE COST; HEALTH ECONOMICS;

COMPARATIVE EFFECTIVENESS RESEARCH; DRUG APPROVAL; DRUG COSTS; DRUGS, GENERIC; ECONOMICS, HOSPITAL; FORECASTING; HEALTH CARE REFORM; HEALTH EXPENDITURES; HUMANS; PHARMACEUTICAL PREPARATIONS; UNITED STATES;

EID: 77955898562     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100068     Document Type: Review

References (31)

1. IMS Health National Sales Perspectives. Analysis conducted by the authors. Analysis conducted July-December 2009.
2. Claxton G, Gabel JR, Dijulio B et al. Health benefits in 2008: premiums moderately higher, while enrollment in consumer-directed plans rises in small firms. Health Aff. 2008; 27:w492-502.
3. Employer Health Benefits 2009 Annual Survey. Exhibit 9.4: among covered workers with three, four, or more tiers of prescription cost sharing, average copayments and average coinsurance, 2000-2009. http://ehbs.kff.org/?page= charts&id=2&sn=24&ch=1139 (accessed 2010 Jan 25).
4. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2009. Am J Health-Syst Pharm. 2009; 66:237-57.
5. Cutler DM. The demise of the blockbuster? N Engl J Med. 2007; 356:1292-3. (Pubitemid 46513294)
6. Wadman M. When the party's over. Nature. 2007; 445:13.
7. Hughes B. 2008 FDA drug approvals. Nat Rev Drug Discov. 2009; 8:93-6.
8. Goldstein J. FDA drug approvals in 2009: up (a little) from 2008. http://blogs.wsj.com/health/2010/01/05/fda-drug-approvals-in-2009-up-a-little- from-2008/ (accessed 2010 Jan 26).
9. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2004. Am J Health-Syst Pharm. 2004; 61:145-58. (Pubitemid 39004639)
10. Lee TH. "Me-too" products - friend or foe? N Engl J Med. 2004; 350:211-2.
11. Rogers EM. Diffusion of innovations. 4th ed. New York: Free Press; 1995.
12. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2006. Am J Health-Syst Pharm. 2006; 63:123-38. (Pubitemid 43100358)
13. Centers for Disease Control and Prevention. 2009 H1N1 flu. www.cdc.gov/H1N1FLU/ (accessed 2009 Dec 17).
14. World Health Organization. Pandemic (H1N1) 2009. www.who.int/csr/disease/ swineflu/en/ (accessed 2009 Dec 17).
15. Hellerman C. Swine flu 'not stoppable,' World Health Organization says. www.cnn.com/2009/HEALTH/06/11/swine.flu.who/ (accessed 2009 Dec 17).
16. Centers for Disease Control and Prevention. Novel H1N1 influenza vaccine. www.cdc.gov/h1n1flu/vaccination/public/vaccination-qa-pub.htm (accessed 2010 Jan 16).
17. Meropol NJ, Schrag D, Smith TJ et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009; 27:3868-74.
18. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009; 27:1492-501.
19. Hartman M, Martin A, Nuccio O et al. Health spending growth at a historic low in 2008. Health Aff. 2010; 29:147-55.
20. Saul S. In sour economy, some scale back on medications. N Y Times. 2008 (Oct 21):A1.
21. Economic forecast for pharma: winter advisory ahead. FDC Rep Pink Sheet. 2008; 70(Nov 3):3.
22. Hodgson J. WHO guidelines presage US biosimilars legislation? Nat Biotechnol. 2009; 27:963-5.
23. Mushlin AI, Ghomrawi H. Health care reform and the need for comparative-effectiveness research. N Engl J Med. 2010; 362:e6.
24. Federal Coordinating Council for Comparative Effectiveness Research. Report to the President and the Congress on comparative effectiveness research. www.hhs.gov/recovery/programs/cer/cerannualrpt.pdf (accessed 2010 Feb 22).
25. Schumock GT, Pickard AS. Comparative effectiveness research: relevance and applications to pharmacy. Am J Health-Syst Pharm. 2009; 66:1278-86.
26. Steinbrook R. Health care and the American Recovery and Reinvestment Act. N Engl J Med. 2009; 360:1057-60.
27. Congressional Budget Office. Research on the comparative effectiveness of medical treatments, December 2007. www.cbo.gov/ftpdocs/88xx/doc8891/12-18- ComparativeEffectivness.pdf (accessed 2010 Feb 22).
28. Medco. Drug trend report. http://insider.ontrackevents.com/portal/DT- 2009-Drug-Trend-Report.pdf (accessed 2010 Jan 25).
29. Express Scripts. 2008 Drug trend report. www.expressscripts.com/ industryresearch/industryreports/drugtrendreport/2008/ (accessed 2010 Jan 25).
30. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2005. Am J Health-Syst Pharm. 2005;62:149-67. (Pubitemid 40674546)
31. American Society of Health-System Pharmacists. ASHP guidelines on medication cost management strategies for hospitals and health systems. Am J Health-Syst Pharm. 2008; 65:1368-84.